MedTrace Logo

Talabostat in Treating Patients With Metastatic Kidney Cancer

NCT00489710 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-08-22

No results posted yet for this study

Summary

RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well talabostat works in treating patients with metastatic kidney cancer.

Conditions

Interventions

DRUG

talabostat mesylate

BIOLOGICAL

enzyme inhibitor therapy

DIAGNOSTIC_TEST

flow cytometry

DIAGNOSTIC_TEST

laboratory biomarker analysis

BIOLOGICAL

non-specific immune-modulator therapy

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Ralph Hauke, MD · University of Nebraska

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-05-30
Completion
2007-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489710 on ClinicalTrials.gov